PRESENCE OF ORGANIC MATTER CONTACT TIME... 13
|
|
|
- Reynard Thomas
- 5 years ago
- Views:
Transcription
1 CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 2 RELATED BCC REPORTS... 3 BCC ONLINE SERVICES... 3 DISCLAIMER... 4 CHAPTER TWO: EXECUTIVE SUMMARY... 5 EXECUTIVE SUMMARY... 5 SUMMARY TABLE WORLDWIDE REVENUE OF ANTISEPTICS AND DISINFECTANTS, THROUGH 2016 ($ MILLIONS)... 6 SUMMARY FIGURE WORLDWIDE REVENUE OF ANTISEPTICS AND DISINFECTANTS, ($ MILLIONS)... 6 CHAPTER THREE: OVERVIEW... 7 DEFINITIONS... 7 MECHANISM OF ACTION OF ANTISEPTICS AND DISINFECTANTS... 8 ACTION ON MEMBRANE... 8 DENATURATION OF CELLULAR PROTEINS... 8 INACTIVATION OF KEY ENZYMES... 9 ALKYLATION OF AMINO-GROUP... 9 DAMAGE TO NUCLEIC ACIDS... 9 SELECTION CRITERIA FOR DISINFECTANT... 9 SPEED OF ACTION EFFICACY HEALTH AND SAFETY ECOLOGICAL PROFILE MATERIAL COMPATIBILITY FACTORS AFFECTING THE ACTIVITY OF DISINFECTANTS LENGTH OF TIME AGE CONCENTRATION AND POTENCY TEMPERATURE PH LEVELS HARDNESS OF WATER MICROBIAL RESISTANCE FACTORS THAT AFFECT THE ACTIVITY OF ANTISEPTICS CONCENTRATION... 12
2 PRESENCE OF ORGANIC MATTER CONTACT TIME CHAPTER FOUR: CLASSIFICATION BIGUANIDES AND AMIDINES POLYHEXANIDE CHLORHEXIDINE PHENOL AND DERIVATIVES PHENOL HEXACHLOROPHENE TRICLOSAN CHLOROXYLENOL PENTACHLOROPHENOL QUATERNARY AMMONIUM COMPOUNDS BENZALKONIUM CHLORIDE BENZETHONIUM CHLORIDE CETRIMONIUM COMPOUNDS CETYLPYRIDINIUM IODINE PRODUCTS POVIDONE IODINE TINCTURE OF IODINE SILVER COMPOUNDS OXIDIZING AGENTS SODIUM HYPOCHLORITE CALCIUM HYPOCHLORITE CHLORAMINES TABLE 1 MONOCHLORAMINES VS. CHLORINE DISINFECTANT CHLORINE DIOXIDE HYDROGEN PEROXIDE ALDEHYDES FORMALDEHYDE GLUTARALDEHYDE ALCOHOLS OTHER ANTISEPTICS AND DISINFECTANTS HYDROXYQUINOLINE DEQUALINIUM CHLOROQUINALDOL OXYQUINOLINE GLYCOLIC ACID OTHER CLASSIFICATION OF ANTISEPTICS AND DISINFECTANTS LOW-LEVEL DISINFECTANTS INTERMEDIATE-LEVEL DISINFECTANTS HIGH-LEVEL DISINFECTANTS... 28
3 CHAPTER FIVE: REGULATORY ASPECTS REGULATORY ASPECTS NEW ANTISEPTICS AND DISINFECTANT APPROVALS TABLE 2 APPROVED DISINFECTANTS AND ANTISEPTICS, TABLE 2 (CONTINUED) TABLE 2 (CONTINUED) TABLE 2 (CONTINUED) TABLE 3 NUMBER OF NEW PRODUCT APPROVALS IN EACH YEAR, FIGURE 1 NUMBER OF NEW PRODUCT APPROVALS, CHAPTER SIX: INDUSTRY STRUCTURE MANUFACTURERS/ SUPPLIERS OF ANTISEPTICS AND DISINFECTANTS BIGUANIDES AND AMIDINES TABLE 4 LEADING MANUFACTURERS/SUPPLIERS OF BIGUANIDES AND AMIDINES TABLE 5 LEADING MANUFACTURERS/SUPPLIERS OF PHENOL AND DERIVATIVES TABLE 5 (CONTINUED) TABLE 6 LEADING MANUFACTURERS/SUPPLIERS OF IODINE AND IODOPHORS TABLE 7 LEADING MANUFACTURERS/SUPPLIERS OF QUATERNARY AMMONIUM PRODUCTS TABLE 7 (CONTINUED) TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF SILVER PRODUCTS TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF ALDEHYDE-BASED PRODUCTS TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF ALCOHOL- BASED PRODUCTS TABLE 10 (CONTINUED) TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF OXIDIZING AGENTS TABLE 11 (CONTINUED) TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF OTHERS CATEGORY AS ANTISEPTICS AND DISINFECTANTS TABLE 12 (CONTINUED) MARKET SHARES OF INDUSTRY LEADERS OF ANTISEPTICS AND DISINFECTANTS BIGUANIDES AND AMIDINES TABLE 13 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BIGUANIDES AND AMIDINES, 2010 (%)... 44
4 FIGURE 2 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BIGUANIDES AND AMIDINES, 2010 (%) PHENOL AND DERIVATIVES TABLE 14 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHENOL AND DERIVATIVES, 2010 (%) FIGURE 3 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHENOL AND DERIVATIVES, 2010 (%) IODINE PRODUCTS TABLE 15 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IODINE PRODUCTS, 2010 (%) FIGURE 4 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IODINE PRODUCTS, 2010 (%) QUARTERNARY AMMONIUM COMPOUNDS TABLE 16 WORLDWIDE MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF QUARTERNARY AMMONIUM COMPOUNDS, 2010 (%) FIGURE 5 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF QUARTERNARY AMMONIUM COMPOUNDS, 2010 (%) SILVER PRODUCTS TABLE 17 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SILVER PRODUCTS, 2010 (%) FIGURE 6 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SILVER PRODUCTS, 2010 (%) ALDEHYDES TABLE 18 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ALDEHYDE-BASED PRODUCTS, 2010 (%) FIGURE 7 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ALDEHYDE-BASED PRODUCTS, 2010 (%) ALCOHOLS TABLE 19 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ALCOHOL-BASED PRODUCTS, 2010 (%) FIGURE 8 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ALCOHOL-BASED PRODUCTS, 2010 (%) OXIDIZING AGENTS... 52
5 TABLE 20 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OXIDIZING AGENTS, 2010 (%) FIGURE 9 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OXIDIZING AGENTS, 2010 (%) OTHERS TABLE 21 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHERS CATEGORY OF ANTISEPTICS AND DISINFECTANTS, 2010 (%) FIGURE 10 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OTHERS CATEGORY OF ANTISEPTICS AND DISINFECTANTS, 2010 (%) CHAPTER SEVEN: NEW DEVELOPMENTS TABLE 22 NEW DEVELOPMENTS, 2008 TO MARCH TABLE 22 (CONTINUED) SOME OTHER DEVELOPMENTS IN RESEARCH INSTITUTES CHAPTER EIGHT: MARKET ANALYSIS Market Revenue TABLE 23 WORLDWIDE MARKET ANTISEPTICS AND DISINFECTANTS, 2009 TO 2016 ($ MILLIONS) FIGURE 11 WORLDWIDE MARKET FOR ANTISEPTICS AND DISINFECTANTS, ($ MILLIONS) BIGUANIDES AND AMIDINES Market Overview Market Revenue TABLE 24 WORLDWIDE MARKET FOR BIGUANIDES AND AMIDINES BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 12 WORLDWIDE MARKET FOR BIGUANIDES AND AMIDINES BY REGION, THROUGH 2016 ($ MILLIONS) PHENOL AND DERIVATIVES Market Overview Market Revenue TABLE 25 WORLDWIDE MARKET FOR PHENOL AND DERIVATIVES BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 13 WORLDWIDE MARKET FOR PHENOL AND DERIVATIVES BY REGION, ($ MILLIONS) IODINE PRODUCTS MARKET OVERVIEW MARKET REVENUE TABLE 26 WORLDWIDE MARKET FOR IODINE PRODUCTS BY REGION, THROUGH 2016 ($ MILLIONS)... 65
6 FIGURE 14 WORLDWIDE MARKET FOR IODINE PRODUCTS BY REGION, ($ MILLIONS) QUATERNARY AMMONIUM COMPOUNDS MARKET OVERVIEW MARKET REVENUE TABLE 27 WORLDWIDE MARKET FOR QUATERNARY AMMONIUM PRODUCTS BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 15 WORLDWIDE MARKET FOR QUATERNARY AMMONIUM PRODUCTS BY REGION, ($ MILLIONS) SILVER PRODUCTS MARKET OVERVIEW MARKET REVENUE TABLE 28 WORLDWIDE MARKET FOR SILVER PRODUCTS BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 16 WORLDWIDE MARKET FOR SILVER PRODUCTS BY REGION, ($ MILLIONS) ALDEHYDE PRODUCTS MARKET OVERVIEW MARKET REVENUE TABLE 29 WORLDWIDE MARKET FOR ALDEHYDE-BASED PRODUCTS BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 17 WORLDWIDE MARKET FOR ALDEHYDE-BASED PRODUCTS BY REGION, ($ MILLIONS) ALCOHOLS MARKET OVERVIEW MARKET REVENUE TABLE 30 WORLDWIDE MARKET FOR ALCOHOL-BASED PRODUCTS BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 18 WORLDWIDE MARKET FOR ALCOHOL-BASED PRODUCTS BY REGION, ($ MILLIONS) OXIDIZING AGENTS MARKET OVERVIEW MARKET REVENUE TABLE 31 WORLDWIDE MARKET FOR OXIDIZING AGENTS BY REGION, THROUGH 2016 ($ MILLIONS) FIGURE 19 WORLDWIDE MARKET FOR OXIDIZING AGENTS BY REGION, ($ MILLIONS) OTHERS MARKET OVERVIEW MARKET REVENUE TABLE 32 WORLDWIDE MARKET FOR OTHERS CATEGORY OF ANTISEPTICS AND DISINFECTANTS BY REGION, THROUGH 2016 ($ MILLIONS)... 79
7 FIGURE 20 WORLDWIDE MARKET FOR OTHERS CATEGORY OF ANTISEPTICS AND DISINFECTANTS BY REGION, ($ MILLIONS) MARKET SHARES OF ANTISEPTICS AND DISINFECTANTS, BY REGION TABLE 33 WORLDWIDE ANTISEPTICS AND DISINFECTANT MARKET SHARES BY REGION, 2010 (%) FIGURE 21 WORLDWIDE ANTISEPTICS AND DISINFECTANT MARKET SHARES BY REGION, 2010 (%) CHAPTER NINE: MARKET BY END USERS TABLE 34 GLOBAL MARKET FOR ANTISEPTICS AND DISINFECTANTS BY END USERS, THROUGH 2016 ($ MILLIONS) FIGURE 22 GLOBAL MARKET FOR ANTISEPTICS AND DISINFECTANTS BY END USERS, ($ MILLIONS) DOMESTIC ANTISEPTICS AND DISINFECTANTS MARKET REVENUE TABLE 35 GLOBAL SALES OF DOMESTIC ANTISEPTICS AND DISINFECTANTS, THROUGH 2016 ($ MILLIONS) FIGURE 23 GLOBAL SALES OF DOMESTIC ANTISEPTICS AND DISINFECTANTS, ($ MILLIONS) Global Share TABLE 36 GLOBAL SHARE OF REGIONS IN DOMESTIC ANTISEPTICS AND DISINFECTANTS IN 2010 (%) FIGURE 24 GLOBAL SHARE OF REGIONS IN DOMESTIC ANTISEPTICS AND DISINFECTANTS IN 2010 (%) INSTITUTIONAL ANTISEPTICS AND DISINFECTANTS MARKET REVENUE TABLE 37 GLOBAL SALES OF INSTITUTIONAL ANTISEPTICS AND DISINFECTANTS, THROUGH 2016 ($ MILLIONS) FIGURE 25 GLOBAL SALES OF INSTITUTIONAL ANTISEPTICS AND DISINFECTANTS, THROUGH 2016 ($ MILLIONS) HEALTH CARE USAGE MARKET REVENUE TABLE 38 GLOBAL SALES OF HEALTH CARE ANTISEPTICS AND DISINFECTANTS, THROUGH 2016 ($ MILLIONS) FIGURE 26 GLOBAL SALES OF HEALTH CARE ANTISEPTICS AND DISINFECTANTS, ($ MILLIONS) GLOBAL SHARE TABLE 39 GLOBAL SHARE FOR HEALTH CARE ANTISEPTICS AND DISINFECTANTS IN 2010 (%) FIGURE 27 GLOBAL SHARE OF HEALTH CARE ANTISEPTICS AND DISINFECTANTS IN 2010 (%) INDUSTRIAL AND COMMERCIAL USE MARKET REVENUE... 90
8 TABLE 40 GLOBAL MARKET FOR ANTISEPTICS AND DISINFECTANTS USED IN INDUSTRIES AND COMMERCIAL PLACES, THROUGH 2016 ($ MILLIONS) FIGURE 28 GLOBAL MARKET FOR ANTISEPTICS AND DISINFECTANTS USED IN INDUSTRIES AND COMMERCIAL PLACES, ($ MILLIONS) GLOBAL SHARE TABLE 41 GLOBAL SHARE FOR INDUSTRIAL AND COMMERCIAL ANTISEPTICS AND DISINFECTANTS, IN 2010 (%) FIGURE 29 GLOBAL SHARE FOR INDUSTRIAL AND COMMERCIAL ANTISEPTICS AND DISINFECTANTS, IN 2010 (%) MARKET SHARE OF APPLICATIONS TABLE 42 SHARE OF ANTISEPTICS AND DISINFECTANTS BY END USERS, IN 2010 (%) FIGURE 30 SHARE OF ANTISEPTICS AND DISINFECTANTS BY END USERS, IN 2010 (%) CHAPTER TEN: PATENT ANALYSIS PATENTS BY YEAR TABLE 43 NUMBER OF SIGNIFICANT PATENTS BY YEAR, (NUMBER/%) FIGURE 31 NUMBER OF SIGNIFICANT PATENTS BY YEAR, FIGURE 32 NUMBER OF PATENTS BY YEAR, (%) PATENTS BY TYPE TABLE 44 NUMBER OF PATENTS BY TYPE, FIGURE 33 PATENTS BY TYPE, (%) FIGURE 33 (CONTINUED) PATENTS BY COMPANY TABLE 45 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTISEPTICS AND DISINFECTANTS, FIGURE 34 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTISEPTICS AND DISINFECTANTS, PATENTS BY COUNTRY TABLE 46 NUMBER OF U.S. PATENTS BY COUNTRY, FIGURE 35 NUMBER OF U.S. PATENTS BY COUNTRY, PATENTS BY ASSIGNEE TYPE TABLE 47 PATENTS BY ASSIGNEE TYPE FOR ANTISEPTICS AND DISINFECTANTS, FIGURE 36 PATENTS BY ASSIGNEE TYPE FOR ANTISEPTICS AND DISINFECTANTS, CHAPTER ELEVEN: STRATEGIES AND PROSPECTS FACTORS AFFECTING THE MARKET OF ANTISEPTICS AND DISINFECTANTS
9 GROWING AWARENESS INVOLVEMENT OF MEDIA SHARP RISE IN INFECTIONS SWINE FLU OUTBREAK GLOBAL INITIATIVES DEMAND OF APPLICATION-SPECIFIC PRODUCTS COMPETITION AND DEMAND MANUFACTURER S STRATEGIES MERGERS AND ACQISITIONS MERGERS AND ACQISITIONS (CONTINUED) CHAPTER TWELVE: COMPANY PROFILES ABC COMPOUNDING COMPANY ACTAVIS AGION TECHNOLOGIES ALDA PHARMACEUTICAL CORPORATION AMERICAN BIOTECH LABS AMREP INC APLICARE INC BIO-CIDE INTERNATIONAL INC BIOTECH MEDICS INC CANTEL MEDICAL CORPORATION CARDINAL HEALTH CAREFUSION CORPORATION CCP INDUSTRIES CLOROX COMPANY (THE) COLGATE PALMOLIVE DALEY INTERNATIONAL LTD DIAL PROFESSIONAL SERIES DIVERSEY INC DOW MICROBIAL CONTROL DUPONT DURABAN ECOLAB INC GOJO INDUSTRIES JOHNSON & JOHNSON M COMPANY MEDICAL CHEMICAL CORP MELROSE CHEMICAL LTD METREX RESEARCH CORPORATION PALMERO HEALTHCARE PROCTER AND GAMBLE COMPANY PROFESSIONAL DISPOSABLES INTERNATIONAL PURE BIOSCIENCES RECKITT BENCKISER
10 SAFETEC OF AMERICA SINOFRESH HEALTHCARE INC SPORICIDIN INTERNATIONAL STEPAN COMPANY STERILEX CORPORATION STERIS CORPORATION VERIDIEN CORPORATION VIROX TECHNOLOGIES XTTRIUM LABORATORIES CHAPTER THIRTEEN: APPENDIX I ABBREVIATIONS/ DEFINITIONS
Background Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy
CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Background Distribution
The above media is designed to purify antibodies from aggregates and other impurities.
Data sheet SepFast TM HighRes Q (400, 500, 600) SepFast TM HighRes DEAE (400, 500, 600) SepFast TM HighRes S (400, 500, 600) SepFast TM HighRes CM (400, 500, 600) 1. Introduction SepFast HighRes Q, SepFast
Test Strips & Colorimetric Analyses
Test Strips & Colorimetric Analyses Range (mg/l = ppm, unless stated) No of tests Type Alkalinity HI-755 0-300 (seawater) 25* HC HI-775 0-500 (fresh water) 25* HC HI-772 0.0 20.00 dkh 25* HC Aluminium
ELEMENTS SHIPPED DRY a. First use in system; b. Twelve (12) months following date of shipment.
Element Warranty DOW FILMTEC Reverse Osmosis / Nanofiltration Element(s) Three- Year Prorated Limited Element Warranty LIMITED WARRANTIES FilmTec Corporation ( hereinafter FilmTec ) provides limited warranties
Enquiries: Ian Johnson Executive Chairman Bioquell PLC Michael Roller Finance Director - 1 -
24 July 2018 Bioquell PLC 2018 interim results Bioquell PLC ( Bioquell ) (LSE symbol: BQE) a leading provider of bio decontamination solutions and modular isolators for the Pharmaceutical, Life Science
FILMTEC Membranes FILMTEC Reverse Osmosis / Nanofiltration Element(s) Three-Year Prorated Limited Element Warranty
Element Warranty FILMTEC Membranes FILMTEC Reverse Osmosis / Nanofiltration Element(s) Three-Year Prorated Limited Element Warranty LIMITED WARRANTIES FilmTec Corporation ( hereinafter FilmTec ) provides
Revised Draft Agenda Biocides Working Group Meeting II-2018
Revised Draft Agenda Biocides Working Group Meeting II-2018 17-25 April 2018 Virtual meeting: TOX WG Physical meetings: APCP, ENV and EFF WGs ECHA Conference Centre (Annankatu 18, Helsinki) Meeting room
J M Loveridge Ltd. Price List Effective from June Mint. Our sales team at JM Loveridge. Tel: E:
J M Loveridge Ltd Price List Effective from June 2016 Mint Our sales team at JM Loveridge. Tel: 01264 367610 E: sales@jmloveridge.com Legal Classification: General Sale List (GSL) We are fully committed
Pressure Seals, Inc. Phone: (877)-PSI-SEAL Toll Free. Thousands of Seals, O-Rings, and U-Cups World-Class Service since 1976!
O-Ring Materials Definition of an Encapsulated O-Ring A circular shaped seal with a round cross section, consisting of two components, a Teflon jacket, and an internal (core) energizer which imparts memory
2015 QUARTERLY REPORT
2015 QUARTERLY REPORT July August September Creating the Improved Standard in Sterile Reprocessing TABLE OF CONTENTS Message from the Chief Executive Officer 1 Overview 2 Third Quarter 2015 and Recent
Pressure BioSciences, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President and CEO Joseph L. Damasio, VP of Finance and CFO (508) 230-1828 (T) (508) 230-1829 (F) Pressure BioSciences, Inc. Reports First
2016 Quarterly Report. July August September. Creating the Improved Standard in Healthcare Sterile Reprocessing
2016 Quarterly Report July August September Creating the Improved Standard in Healthcare Sterile Reprocessing Contents Message from the Chief Executive Officer... 1 Overview... 3 Third Quarter 2016 and
The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE**
The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE** Pharmaceutical, commercial and strategic developments in the Brazil, Russia, India & China Over-the- Counter
S-Network Sector Dividend Dogs Index
S-Network Sector Dividend Dogs Index Q4 2017 Index Rationale Well-Established Universe of Index Candidates S&P 500 Serves as Universe for SDOGX Comprises of 50 Constituents Stocks Must Meet All Screens
Nanogen Epoch Biosciences Merger Frequently Asked Questions
Filed by Nanogen, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Epoch Biosciences, Inc.
Nuva Pharmaceuticals Inc. Management s Discussion & Analysis For the Three and Nine Month Periods Ended March 31, 2014 and 2013
Nuva Pharmaceuticals Inc. Management s Discussion & Analysis For the Three and Nine Month Periods Ended Section Description Page 1.01 Date 2 1.02 Overall Performance 2 1.03 Selected Annual Information
Clorox Provides Preliminary Second Quarter Financial Information and Fiscal Year Sales Range Update; Announces Goodwill Impairment
NEWS RELEASE Clorox Provides Preliminary Second Quarter Financial Information and Fiscal Year Sales Range Update; Announces Goodwill Impairment 1/3/2011 OAKLAND, Calif., Jan. 3, 2011 The Clorox Company
> Important Notice Corporate Presentation
June 2015 > Important Notice Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other financial
Clorox Reports Q1 Fiscal Year 2018 Results; Updates Fiscal Year 2018 Outlook
NEWS RELEASE Clorox Reports Q1 Fiscal Year 2018 Results; Updates Fiscal Year 2018 Outlook 11/1/2017 OAKLAND, Calif., Nov. 1, 2017 /PRNewswire/ -- The Clorox Company (NYSE:CLX) reported sales growth of
MFS LOW VOLATILITY EQUITY FUND
QUARTERLY REPORT November 30, 2017 MFS LOW VOLATILITY EQUITY FUND PORTFOLIO OF INVESTMENTS 11/30/17 (unaudited) The Portfolio of Investments is a complete list of all securities owned by your fund. It
FOR IMMEDIATE RELEASE SQM REPORTS EARNINGS FOR THE FIRST NINE MONTHS OF 2002
Highlights FOR IMMEDIATE RELEASE SQM REPORTS EARNINGS FOR THE FIRST NINE MONTHS OF 2002 Earnings per ADR increased 37.8% from US$0.84 for the nine-month period ended September 30, 2001, to US$1.15 for
Case No COMP/M DUPONT / TEIJIN. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 24/11/1999
EN Case No COMP/M.1599 - DUPONT / TEIJIN Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 24/11/1999 Also available in
Sunbeam Auto Pvt. Ltd., Testing Research & Development Centre, 38/6 Km Stone, Delhi-Jaipur Highway, Narsingpur, Gurgaon, Haryana
Last Amended on 29.01.2016 Page 1 of 12 I. METALS & ALLOYS 1. & Steel (Pain Carbon Steel, Stainless Steel, Tool Steel) By Wet Method Carbon IS 228 (Part 1,4): 2008 IS 228 (Part 2): 2008, IS 12308 (Part
SQM at a Glance. Contribution to Revenue vs. Gross Profit 6M2018 (2) 57% 36% 20% 14% 30% 13% 12% 4% F E R T I L I Z E R S
SQM 2Q208 RESULTS Important Notice SQM Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other
First Half-Year / Second Quarter Results 30 JULY July 2015
First Half-Year / Second Quarter Results 30 JULY 2015 First Half-Year 3 First Half-Year / Second Quarter Results 2015 First Half-Year improved profitability and cash generation in a challenging market
Summary report on the 11 th meeting of the ASEAN Cosmetic Scientific Body (ACSB) The meeting was held on June 23, 2009 in Kuala Lumpur
Summary report on the 11 th meeting of the ASEAN Cosmetic Scientific Body (ACSB) The meeting was held on June 23, 2009 in Kuala Lumpur The following issues were discussed. Item Content Conclusion The meeting
Bioquell PLC. Interim Report & Accounts
Bioquell PLC Interim Report & Accounts 2018-1 - Contents 1. Financial highlights 3 2. Operational highlights 3 3. Chairman s Statement 4 4. Introduction 4 5. Business Review 4 6. Financial Results 6 7.
Cantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2018
Cantel Medical Reports Financial Results for its Third Quarter Fiscal Year 2018 May 31, 2018 Strong performance across all divisions fuels growth - Net sales of $217.3M, up 13.1%, with organic sales growth
Important Notice Corporate Presentation
May 2016 Important Notice Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other financial items,
SQM at a Glance. Contribution to Revenue vs. Gross Profit 1H Twelve months ended June 30, Excluding Others
SQM 2Q2017 RESULTS Important Notice SQM Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other
gets it done Fiscal
S T E R I S S T E R I S gets it done G E T S I T D O N E Fiscal 2 0 0 2 A N N U A L R E P O R T CONTENTS STERIS At a Glance inside front cover Financial Highlights 1 Shareholder Letter 2 Where STERIS Gets
CUSTOMARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
SQM 3Q2018 RESULTS CUSTOMARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements in this presentation concerning the Company s business outlook, future economic performance, anticipated profitability,
Investor Presentation. March 2018
Investor Presentation March 2018 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities
The Chemours Company. Investor Presentation. March 2017
The Chemours Company Investor Presentation March 2017 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of the federal securities laws, that
For Consultation WORKPLACE SAFETY AND HEALTH ACT (CHAPTER 354A) WORKPLACE SAFETY AND HEALTH (MAJOR HAZARD INSTALLATIONS) REGULATIONS 2016
WORKPLACE SAFETY AND HEALTH ACT (CHAPTER 354A) WORKPLACE SAFETY AND HEALTH (MAJOR HAZARD INSTALLATIONS) REGULATIONS 2016 ARRANGEMENT OF REGULATIONS PART 1 PRELIMINARY Regulation 1. Citation and commencement
Q Creating the Improved Standard in Healthcare Sterilization Quarterly Report Q3 July, August, September
Creating the Improved Standard in Healthcare Sterilization 2010 Quarterly Report Q3 July, August, September ii INDEX MESSAGE FROM THE CHIEF EXECUTIVE OFFICER... 1 OUR INDUSTRY... 3 MD&A INTRODUCTORY COMMENTS...
First Quarter 2017 Earnings Presentation
First Quarter 2017 Earnings Presentation Important Notice Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues,
Phibro Animal Health Corporation
Phibro Animal Health Corporation 27 th Annual Healthcare Conference Cautionary Statements Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and
Letter to our Shareholders: August 4, 2011
Letter to our Shareholders: August 4, 2011 Fiscal 2011 was a transformational year for Mesa Labs. Early in the year we completed the acquisition of SGM Biotech, Inc., in Bozeman, Montana, and at the end
Nine-month figures for 2017: Sartorius continues to grow profitably in a challenging environment
Nine-month figures for : Sartorius continues to grow profitably in a challenging environment Group revenue up 8.6%; despite unfavorable currency effects, earnings 1 up 7.3% The Lab Products & Services
Creating a Global Leader in Sustainable Solutions that Provide Hygiene, Protection, Food Safety and Security Sealed Air s Acquisition of Diversey
Creating a Global Leader in Sustainable Solutions that Provide Hygiene, Protection, Food Safety and Security Sealed Air s Acquisition of Diversey June 1, 2011 Safe Harbor and Regulation G Statement This
Case No COMP/M DUPONT / SABANCI. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 24/11/1999
EN Case No COMP/M.1538 - DUPONT / SABANCI Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 24/11/1999 Also available in
Keith Nichols, CFO September, Credit Investor Meetings
Keith Nichols, CFO September, 2008 Credit Investor Meetings Safe Harbor Statement This presentation contains statements which address such key issues as AkzoNobel s growth strategy, future financial results,
Sree Rayalaseema High-Strength Hypo Ltd.
CMP `96.40 Recommended Price `85.00 Anticipated Price `150.00 View 1 Year & Above Sree Rayalaseema Hi-Strength Hypo Ltd (SRHH), part of TGV Group is the only Indian manufacturer of Calcium Hypochlorite
Fully diluted net income per share
Summary of Consolidated Financial Results For the Third Quarter of the Fiscal Year Ending March 31, 2009 (Nine Months Ended December 31, 2008) February 6, 2009 Company name: Nippon Shokubai Co., Ltd. Listing:
CITY OF MT. PLEASANT, MICHIGAN CONTRACT DOCUMENTS. For 2018 WATER TREATMENT PLANT CHEMICALS BID. KATHLEEN LING Mayor. NANCY RIDLEY City Manager
CITY OF MT. PLEASANT, MICHIGAN CONTRACT DOCUMENTS For 2018 WATER TREATMENT PLANT CHEMICALS BID KATHLEEN LING Mayor NANCY RIDLEY City Manager Prepared By: Division of Public Works JOHN ZANG DPW Director
WASTEWATER TREATMENT FACILITY
WASTEWATER TREATMENT FACILITY ANNUAL BUDGET ESTIMATE - EXPENDITURE Amended - 2017-2018 CITY OF BREVARD FY 2016-2017 2015-2016 2016-2017 6/30/2017 2016-2017 2017-2018 Account Actual ($) Budget ($) Actual
No. S 202 WORKPLACE SAFETY AND HEALTH ACT (CHAPTER 354A) WORKPLACE SAFETY AND HEALTH (MAJOR HAZARD INSTALLATIONS) REGULATIONS 2017
1 First published in the Government Gazette, Electronic Edition, on 2 May 2017 at 5 pm. No. S 202 WORKPLACE SAFETY AND HEALTH ACT (CHAPTER 354A) WORKPLACE SAFETY AND HEALTH (MAJOR HAZARD INSTALLATIONS)
Traditional Life Cycle of a company. Growth Phase
Today s Mid Caps are the Large Caps of tomorrow Traditional Life Cycle of a company Start-up Phase Growth Phase Mature Phase Emerging companies High growth phase But prone to higher risks Business not
Biosenta Inc. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED DECEMBER 31, 2014 AND 2013
Biosenta Inc. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED DECEMBER 31, 2014 AND 2013 The following management discussion and analysis ( MD&A ) of financial results is dated March 2, 2015
Cholesterol Testing/Monitoring Drug and Alcohol Screening Glucose Testing and Monitoring Infectious Disease Testing...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 DEFINING POC... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 3 RELATED REPORTS... 3 BCC
To Create and Deliver the New Standard of Care in Sterile Reprocessing TM 2017 ANNUAL REPORT
To Create and Deliver the New Standard of Care in Sterile Reprocessing TM 2017 ANNUAL REPORT Table of Contents Message from the Chairman of the Board and the President and Chief Executive Officer 1 Overview
TSO 3 Reports Record Fourth Quarter and Full Year 2016 Results
TSO 3 Reports Record Fourth Quarter and Full Year 2016 Results Québec City, March 21, 2017 TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices
plc Interim results presentation 31 December 2014 Paul Swinney - CEO Liz Dixon - FD
plc Interim results presentation 31 December 2014 Paul Swinney - CEO Liz Dixon - FD 1 Financial highlights Revenue up 15% to 7.4m (2013: 6.4m) International sales up 26% to 2.4m (2013: 1.9m) Pre-tax profit
Third Quarter Fiscal 2010 Sales and Earnings
Third Quarter Fiscal 2010 Sales and Earnings Eric Krasnoff Chairman & CEO June 9, 2010 Sustainable, Profitable Growth Forward Looking Statements The matters discussed in this presentation contain forward-looking
DEPARTMENT OF HOMELAND SECURITY. U.S. Customs and Border Protection. Notice of Issuance of Final Determination Concerning.
This document is scheduled to be published in the Federal Register on 07/09/2018 and available online at https://federalregister.gov/d/2018-14632, and on FDsys.gov DEPARTMENT OF HOMELAND SECURITY U.S.
Q Creating the Improved Standard in Healthcare Sterilization Quarterly Report Q1 January, February, March
Creating the Improved Standard in Healthcare Sterilization 2010 Quarterly Report Q1 January, February, March INDEX MESSAGE FROM THE CHIEF EXECUTIVE OFFICER... 1 INTRODUCTORY COMMENTS... 3 THE PLAN... 3
TOMI ENVIRONMENTAL SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event
SQM at a Glance. Contribution to Revenue vs. Gross Profit 1Q % 36% 32% 19% 14% 11% 6% 10% 4% F E R T I L I Z E R S
SQM 1Q018 RESULTS Important Notice SQM Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other
Fully diluted net income per share Dividend per share (Record date) End of 1Q End of 2Q End of 3Q Year-end Annual
NIPPON SHOKUBAI CO., LTD. (4114) Financial Results for the Second Quarter of FY3/11 Summary of Consolidated Financial Results For the Second Quarter of the Fiscal Year Ending March 31, 2011 (Six Months
DSM in motion: driving focused growth
DSM in motion: driving focused growth Nico Gerardu Member of the Managing Board Nomura Chemicals Conference Rome, 22 March 2012 Safe harbor statement This presentation may contain forward-looking statements
The Poliwogg BioPharma M&A Index
The Poliwogg BioPharma M&A Index Q4 2016 Industry Background Scientific Innovations Driving Opportunities: Increasing Understanding of Disease Mechanism Genomics Enabling Precision Medicine Better Therapeutics
Clorox Reports Strong 12 Percent EPS Growth for Its Full Fiscal Year, With Solid Q4 Results; Confirms Fiscal 2011 Outlook
NEWS RELEASE Clorox Reports Strong 12 Percent EPS Growth for Its Full Fiscal Year, With Solid Q4 Results; Confirms Fiscal 2011 Outlook 8/3/2010 OAKLAND, Calif., Aug. 3, 2010 - The Clorox Company (NYSE:
STERIS Investor Presentation November 6, 2018
STERIS Investor Presentation November 6, 2018 Forward Looking Statements This presentation may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking
PUBLIC NOTICE OF MINISTRY OF COMMERCE NO.62 OF YEAR Initiation of Antidumping Investigation on Hydriodic Acid Originating in the US and Japan
PUBLIC NOTICE OF MINISTRY OF COMMERCE NO.62 OF YEAR 2017 Initiation of Antidumping Investigation on Hydriodic Acid Originating in the US and Japan On September 6, 2017, the Ministry of Commerce ( MOFCOM
Investor Presentation. March 2018
Investor Presentation March 2018 Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities
Kemira s Growth Continues from the Pole Position
1 Kemira s Growth Continues from the Pole Position Lasse Kurkilahti, President & CEO 7 February 2006 IR Contact: Päivi Antola, paivi.antola@kemira.com, tel. +358 1086 21140 Contents 2005 Group Highlights
Q Creating the Improved Standard in Healthcare Sterilization Quarterly Report Q2 April, May, June
Creating the Improved Standard in Healthcare Sterilization 2010 Quarterly Report Q2 April, May, June INDEX MESSAGE FROM THE CHIEF EXECUTIVE OFFICER... 1 OUR INDUSTRY... 3 MD&A INTRODUCTORY COMMENTS...
BIOLOGICAL CONTAMINATION CONTROL TECHNOLOGIES LIFE SCIENCES: ASEPTIC FACILITIES FOR BIOLOGICS/BIOTECHNOLOGY
BIOLOGICAL CONTAMINATION CONTROL TECHNOLOGIES LIFE SCIENCES: ASEPTIC FACILITIES FOR BIOLOGICS/BIOTECHNOLOGY HEALTHCARE: COMBATING HOSPITAL ACQUIRED INFECTION AND ANTIBIOTIC RESISTANCE DEFENCE: SPECIALIST
Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2018
Cantel Medical Reports Financial Results for its Fourth Quarter Fiscal Year 2018 September 27, 2018 Strong fourth quarter closes record year in line with management expectations - Net sales of $228.9M,
Price List Effective from. January Tel: Fax:
Price List Effective from January 2017 Tel: 01264 367 610 Fax: 01264 351 761 Email: sales@jmloveridge.com www.jmloveridge.com JML news: J M Loveridge is proud to announce that our brand new website has
CHAPTER 2: CONSTRUCTING FINANCIAL STATEMENTS
M2-18. a. no effect e. increase b. decrease f. increase c. decrease g. increase d. no effect M2-19. a. Balance sheet e. Balance sheet i. Income statement b. Income statement f. Balance sheet j. Income
BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD
1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018
C.R. Bard Inc Cameron Health Inc CardioTech International Cook Medical Inc Conor Medsystems Cordis Corin Group...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOAL AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 SCOPE AND FORMAT... 2 TECHNOLOGIES... 2 HEALTHCARE AREAS... 3 COUNTRIES AND REGIONS...
Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route
Aurum Equity Partners LLP Aurum Insights Pharmaceuticals October 2014 Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route Read more
The price bid evaluation statement has been made taking into consideration the following relevant points -
PROCEEDINGS OF THE TENDER EVALUATION COMMITTEE MEETING HELD ON 03.10.2016 AT 3.30 P.M. IN THE TENDER HALL OF OSMC, BHUBANESWAR FOR EVALUATION OF PRICE BID FOR THE DRUGS & CONSUMABLES GROUP II. [Bid Ref.
Quarterly Report July 31, 2018 MFS. Global Growth Fund
Quarterly Report July 31, 2018 MFS Global Growth Fund PORTFOLIO OF INVESTMENTS 7/31/18 (unaudited) The Portfolio of Investments is a complete list of all securities owned by your fund. It is categorized
FOR IMMEDIATE RELEASE CARDINAL HEALTH REPORTS FIRST QUARTER RESULTS
7000 Cardinal Place Dublin,OH 43017 www.cardinalhealth.com FOR IMMEDIATE RELEASE Contacts: Media: Troy Kirkpatrick (614) 757-6225 troy.kirkpatrick@cardinalhealth.com Investors: Sally Curley (614) 757-7115
CHEMICAL COMPANY OF MALAYSIA BERHAD (CCM) Q2 AND H RESULTS 29 AUGUST 2018
CHEMICAL COMPANY OF MALAYSIA BERHAD (CCM) Q2 AND H1 2018 RESULTS 29 AUGUST 2018 THE AGENDA FOR TODAY CONTENTS OF PRESENTATION BRIEF ON CCM 1 2 FINANCIAL OVERVIEW OVERVIEW BY BUSINESS 3 4 WAY FORWARD 2
Quarterly Report January 31, 2018 MFS. Global Growth Fund
Quarterly Report January 31, 2018 MFS Global Growth Fund PORTFOLIO OF INVESTMENTS 1/31/18 (unaudited) The Portfolio of Investments is a complete list of all securities owned by your fund. It is categorized
April Fourth Quarter 2016 Earnings Presentation
April 2017 Important Notice Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other financial
Clorox Delivers 26 Percent EPS Growth in Q2, Driven by Strong Volume, Sales and Gross Margin Increases
NEWS RELEASE Clorox Delivers 26 Percent EPS Growth in Q2, Driven by Strong Volume, Sales and Gross Margin Increases 2/4/2010 OAKLAND, Calif., Feb. 4, 2010 - The Clorox Company (NYSE: CLX) today reported
Precious Metals Index. The main purpose of introducing the precious metals index is to provide a different vehicle of investment for traders.
MEX NEPAL YEAR BOOK - 2011 Research Paper Precious Metals Index The main purpose of introducing the precious metals index is to provide a different vehicle of investment for traders. 1) Precious Metals
THE CHEMOURS COMPANY 2016 ANNUAL REPORT. Reinvigorated. A year of transformation.
THE CHEMOURS COMPANY 2016 ANNUAL REPORT Reinvigorated. A year of transformation. A Note from Richard and Mark 2016 financial and business performance results: Fellow Shareholders, For Chemours, 2016 was
STRONG START TO 2009
A World Leader in Household, Health and Personal Care 28 April 2009 STRONG START TO 2009 Results at a glance Q1 % change % change actual exchange constant exchange m Net revenue 1,911 +27 +8 Operating
The Subsurface Mineral Regulations, 1960
1 The Subsurface Mineral Regulations, 1960 being Saskatchewan Regulations 541/67 (effective September 6, 1960) as amended by Saskatchewan Regulations 558/64, 536/67, 8/68, 167/70, 94/75, 271/86, 45/87,
Quarterly Report August 31, Massachusetts Investors Growth Stock Fund
Quarterly Report August 31, 2018 Massachusetts Investors Growth Stock Fund PORTFOLIO OF INVESTMENTS 8/31/18 (unaudited) The Portfolio of Investments is a complete list of all securities owned by your fund.
Quarterly Report March 31, 2018 MFS. Global Equity Series. MFS Variable Insurance Trust
Quarterly Report March 31, 2018 MFS Global Equity Series MFS Variable Insurance Trust PORTFOLIO OF INVESTMENTS 3/31/18 (unaudited) The Portfolio of Investments is a complete list of all securities owned
ATBC FINANCIAL REPORT
By Patricia Delamônica Sampaio, Treasurer ATBC Council Meeting, 20 July 2014 Cairns, Australia 2013 SUMMARY Kaoru Kitajima stepped down as ATBC s Treasurer at the end of July 2013 after wrapping up the
S-Network Large-Cap Sharpe Ratio Index
S-Network Large-Cap Sharpe Ratio Index Q4 2018 Index Rationale The Sharpe Ratio is a Key Measure of Financial Performance The Sharpe Ratio is Widely Used by Financial Professionals The Sharpe Ratio is
Summary of Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 (IFRS Basis)
Summary of Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 (IFRS Basis) Date: February 14, 2019 Listed company name: Nitto Denko Corporation Stock exchange listing: First
Conference Call First-Quarter 2017 Results. Joachim Kreuzburg, CEO April 24, 2017
Conference Call First-Quarter 2017 Results Joachim Kreuzburg, CEO April 24, 2017 Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019 November 29, 2018 Medical segment leads with strong double-digit growth - Net sales of $225.6M, up 6.0%, with organic sales
DISHMAN CARBOGEN AMCIS LIMITED. Q3 & 9M FY18 RESULTS UPDATE January 2018
DISHMAN CARBOGEN AMCIS LIMITED Q3 & 9M FY18 RESULTS UPDATE January 2018 1 SAFE HARBOR STATEMENT This presentation and the following discussion may contain forward looking statements by Dishman Carbogen
SQM at a Glance. Contribution to Revenue vs. Gross Profit % 32% 30% 18% 9% 19% 12% 7% F E R T I L I Z E R S
SQM 2017 RESULTS Important Notice SQM Statements in this presentation concerning the Company s business outlook or future economic performances, anticipated profitability, revenues, expenses, or other
QUARTERLY REPORT September 30, 2017 MFS GLOBAL EQUITY SERIES. MFS Variable Insurance Trust
QUARTERLY REPORT September 30, 2017 MFS GLOBAL EQUITY SERIES MFS Variable Insurance Trust PORTFOLIO OF INVESTMENTS 9/30/17 (unaudited) The Portfolio of Investments is a complete list of all securities
Bioquell PLC. Interim Report & Accounts 2017
Bioquell PLC Interim Report & Accounts 2017 Bioquell PLC Contents Interim Report & Accounts 2017 FINANCIAL HIGHLIGHTS... 3 OPERATIONAL ACTIVITIES... 3 CHAIRMAN S STATEMENT... 4 CONSOLIDATED INCOME STATEMENT...
Business Update March 2012
Business Update March 2012 Special note regarding forward-looking statements Certain statements contained in this presentation constitute forward-looking statements within the meaning of certain securities
Segregation. (4) Segregation is not required:
176.83 Segregation. (a) General. (1) The requirements of this section apply to all cargo s on or under of all types of vessels, and to all cargo transport units. (2) Segregation is obtained by maintaining
SAMPLE. Japan Petrochemicals Industry Outlook to Market Size, Company Share, Price Trends and Capacity Forecasts
Japan Petrochemicals Industry Outlook to 2016 - Market Size, Company Share, Price Trends and Capacity Forecasts Reference Code: GDCH0032CAR Publication Date: DECEMBER 2012 GlobalData. This report is a